The efficacy of methotrexate-impregnated hydroxyapatite composites on human mammary carcinoma cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 17429119.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To investigate the efficacy of local biodegradable composites of hydroxyapatite, plaster of Paris, and a binder of either alginate or chitosan impregnated with methotrexate on human mammary carcinoma cells. An in vitro analysis of drug dissolution and a cytotoxicity test on human mammary carcinoma cells were performed over one month. Physicochemical properties of each composite were investigated using scanning electron microscopy, X-ray diffractometry, and Fourier transform infrared spectroscopy. Both composites with a binder of either alginate or chitosan could release methotrexate for over one month. The amount of methotrexate released depended on the amount of methotrexate loaded. The composite using alginate as a binder released a significantly greater amount of methotrexate than that using chitosan as a binder (p<0.05). The elution of both composites showed favourable cytotoxicity when the concentration was greater than 5 microg/ml. Methotrexate-impregnated hydroxyapatite composites appear to be effective local skeletal methotrexate delivery systems against human mammary carcinoma cells in an in vitro model.
Medical subject headings
- Breast Neoplasms
- Calcium Sulfate
- Drug Carriers
- Hydroxyapatites
- Methotrexate